Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in oral drug delivery platforms, announces its attendance at the BIO International Convention (BIO) from June 22-25 in San Diego, CA. The company’s participation follows last year’s convention, which served as a catalyst for an expanded business development (BD) program that is now yielding positive results.
“We are experiencing record-high levels of business development and collaboration interest in our DehydraTECH platform, even before the upcoming BIO conference,” said Richard Christopher, CEO of Lexaria Bioscience. “New business relationships require intense energy and scientific evaluation from both prospective partners to discover the best fit possible. We are working tirelessly in this regard with the intent of generating positive developments that we can publicly discuss.”
BIO is the largest convention of its kind, with over 20,000 attendees expected from the global pharmaceutical and biotechnology industries, as well as supporting sectors such as investors and finance professionals. The 2025 conference saw over 66,000 partnering meetings. Lexaria has already begun reserving meetings and expects to be fully booked given strong industry interest in its proprietary DehydraTECH drug delivery platform.
BIO is the latest example of a multi-faceted BD program that Lexaria quietly launched to inform prospective business partners of the benefits available through DehydraTECH. Although confidential information cannot be publicly disclosed, Lexaria’s BD program has already generated collaborative and potential business partnering discussions with a range of companies, from innovative smaller biotech developers to well-known global pharmaceutical giants.
While the BD program has developed numerous ongoing discussions, Lexaria continues to develop additional early-stage leads. The company intends to thoroughly evaluate each potential relationship and pursue only those in the best interests of its shareholders. Additional information will be made available when appropriate.
DehydraTECH is Lexaria’s patented drug delivery formulation and processing platform technology that improves how a wide variety of drugs enter the bloodstream through oral delivery. The platform has repeatedly evidenced the ability to increase bio-absorption, reduce side-effects, and deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 65 patents granted and additional patents pending worldwide. For more information, visit www.lexariabioscience.com.
This press release includes forward-looking statements identified by words such as “anticipate,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and similar expressions. These statements reflect the company’s best judgment based on current information and involve risks and uncertainties. Factors that could cause actual results to differ include market conditions, government regulation, litigation, competition, and scientific discovery. There is no assurance that Lexaria’s postulated uses, benefits, or advantages for its patent-pending technology will be realized. No statement has been evaluated by the FDA, and Lexaria-associated products are not intended to diagnose, treat, cure, or prevent any disease.